Lupin receives USFDA nod for Lorazepam Oral Concentrate

Drug firm Lupin today said it has received US health regulator's approval to market its generic Lorazepam Oral Concentrate, used for treating anxiety disorders, in the American market.

Lupin Pharmaceuticals Inc, a subsidiary of Lupin, has received final approval from US Food and Drug Administration (USFDA) for its Lorazepam Oral Concentrate USP, Lupin Ltd said in a statement.

The Mumbai-headquartered firm's product is a generic version of Roxane Inc's Lorazepam Intensol and is indicated for the management of anxiety disorders or for the short- term relief of the symptoms of anxiety or anxiety associated with depressive symptoms, it added.

According to IMS MAT September 2012 sales data, Lorazepam Oral Concentrate had annual US sales of nearly $10.7 million.

Lupin scrip closed at Rs 594 on the BSE, down 0.21 per cent from its previous close.

EDITORIAL OF THE DAY

  • It is for the market, not the government to decide the fares of private air carriers

    In a country where substantial lip service is paid to the glories of a free economy and laissez faire, there is enough evidence to suggest that in rea

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Urs Schoettli

New masters of the Financial Times

A few days ago, Japan’s leading financial daily Nihon Keizai ...

Anuja Sharma

Focus mindfully to get the result

Have you ever tried to light a fire using the ...

Gautam Gupta

Our fashion schools need to notch it up

“Creativity is the key to success and primary education is ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture